The Rectal Cancer M1 Study is a Phase II study evaluating short course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer.

Eligibility
Primary metastasized rectal cancer
Resectable metastases
Good general condition
No history of cardiac disease
Treatment
5x5 Gy radiation therapy
6 cycles of capecitabine, oxaliplatin and bevacizumab
resection of primary tumor and metastases
Primary endpoint
Percentage of radical resection or ablation of both primary tumor and metastases
Study coordinator
Klaas Havenga, department of surgery, University Medical Center Groningen, e-mail: k.havenga@chir.umcg.nl

Website: www.m1-rectalcancer.org

With 50 patients included this study is closed. We hope to present data, results, primary endpoint, toxicity and complications in 2010.